2022 Impact Report

The Impact Report is designed as an easy-to-scan snapshot of statistics and stories. You can get data on trial activations, trial closures, enrollment, membership, and publications and presentations, and you can learn about SWOG's impact and accomplishments. That said, it is a snapshot, demonstrating where we were recently, but not necessarily where we are going. Nonetheless, it definitely offers a lot of key information about how our group is doing overall.

You can view the 2022 report here.

It highlights some significant ways we’ve changed the practice of cancer medicine over the past year:

• The results of our S1800A trial led to an FDA “breakthrough designation” for the combination of ramucirumab and pembrolizumab in patients with advanced non-small cell lung cancer (these results also led to the design of a truly groundbreaking phase III confirmatory trial, set to launch this month – but you’ll have to click through to the Impact Report to read more about that).
   
• Our S1512 results in desmoplastic melanoma have changed clinical practice and are expected to significantly reduce the extent of potentially disfiguring surgery faced by many patients.
   
• Our S1801 results in advanced melanoma have also changed clinical practice, by demonstrating that starting immunotherapy in these patients before surgery rather than waiting until after significantly reduces their risk of recurrence.

And it offers some noteworthy numbers:

• We delivered 85 abstracts and presentations last year, the highest count since we started producing these Impact Reports in 2016.
   
• We gave 36 presentations at ASCO, which is a record at least as far back as 2000.
   
• In our last report we told you that four decades of NCTN trials had given 14 million life-years to patients with cancer. In this report we attach a price tag to those years – they cost only $326 of federal investment per life-year.

One number that fell compared to last year is the number of trials that reached the point of activation between January 1 and December 31 – it fell from 10 in 2021 to only 7 in 2022. 

But this number doesn’t at all convey the impressive cue of protocols we have approaching activation. In fact, we have 26 SWOG protocols now in development, more than one half of which are expected to activate by summer.

And that count doesn’t even include the first cohort of SWOG CTP protocols now in late production. 

Every year is unique, and in 2022 we produced much that was memorable. And I am proud of it.

I invite you to check out our 2022 report!